Company Overview - Tectonic Therapeutics is focused on the discovery and development of both agonist and antagonist biologics targeting GPCRs (G protein-coupled receptors) [2] - The executive team has extensive experience, having led teams that resulted in over 20 first approvals of drugs and numerous follow-up indications [2] Product Pipeline - Tectonic has a robust product pipeline aimed at high unmet need areas with multibillion-dollar market potential [2] - Currently, the company has 2 programs in the clinic covering 3 indications, along with a strong emerging preclinical pipeline [3] - One of the key programs is TX45, a long-acting relaxin, which is in Phase II for pulmonary hypertension associated with preserved ejection fraction and heart failure [3]
Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript